Key Action Statement Profile: KAS 5A
| Aggregate evidence quality | Grade B |
| Benefits | No adverse effects from antibiotic. Reduces potential for development of bacterial resistance. Reduced costs. |
| Risks, harms, cost | Small increase in episodes of AOM. |
| Benefit-harm assessment | Preponderance of benefit. |
| Value judgments | Potential harm outweighs the potential benefit. |
| Intentional vagueness | None. |
| Role of patient preferences | Limited. |
| Exclusions | Young children whose only alternative would be tympanostomy tubes. |
| Strength | Recommendation |
| Aggregate evidence quality | Grade B |
| Benefits | No adverse effects from antibiotic. Reduces potential for development of bacterial resistance. Reduced costs. |
| Risks, harms, cost | Small increase in episodes of AOM. |
| Benefit-harm assessment | Preponderance of benefit. |
| Value judgments | Potential harm outweighs the potential benefit. |
| Intentional vagueness | None. |
| Role of patient preferences | Limited. |
| Exclusions | Young children whose only alternative would be tympanostomy tubes. |
| Strength | Recommendation |